The Future of Diagnostics, Artificial Intelligence & Regulatory Innovations

Oncology Times covered a Friends of Cancer Research meeting where Joe Franklin served as a panelist. Joe explained the need for evolving AI governance and regulatory adaptation to address the iterative nature of AI-driven diagnostics, while ensuring patient safety and clinical utility. Joe’s panel was part of a series of discussions to further understand diagnostic test variability in support of improving precision medicine.

“AI is not a static tool; it is not a slide rule,” Joe said. While regulatory flexibility is needed for the fast-paced field of AI-driven tools in healthcare, he noted that, in general, institutions are slow in incorporating computer-driven innovations into their daily workflow.